We can’t show the full text here under this license. Use the link below to read it at the source.
Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide
Ketoacidosis with Normal Blood Sugar After Using Both an SGLT2 Inhibitor and Tirzepatide
AI simplified
Abstract
A patient developed after starting and an SGLT2 inhibitor for type 2 diabetes.
- Euglycemic ketoacidosis is a serious condition that can lead to systemic acidosis and organ damage.
- Unlike diabetic ketoacidosis, patients with euglycemic ketoacidosis have normal to slightly elevated blood glucose levels.
- The condition has been increasingly associated with and GLP-1 receptor agonists.
- This case is the first reported instance of euglycemic ketoacidosis occurring following the initiation of tirzepatide.
- The patient required intensive care for treatment and monitoring to achieve full recovery.
- Awareness of this rare but potentially fatal complication is important for clinicians prescribing tirzepatide.
AI simplified